Literature DB >> 15618545

Human urotensin II is a novel activator of NADPH oxidase in human pulmonary artery smooth muscle cells.

Talija Djordjevic1, Rachida S BelAiba, Steve Bonello, Josef Pfeilschifter, John Hess, Agnes Görlach.   

Abstract

BACKGROUND: Human urotensin II (hU-II) is a potent vasoactive peptide possibly involved in pulmonary hypertension. Because the signaling mechanisms activated by this peptide in the pulmonary vasculature are largely unknown, we investigated the role of hU-II in the activation of NADPH oxidase and the control of redox-sensitive kinase pathways, expression of plasminogen activator inhibitor-1 (PAI-1), and proliferation in pulmonary artery smooth muscle cells (PASMCs). METHODS AND
RESULTS: hU-II upregulated expression of the NADPH oxidase subunits p22phox and NOX4 and increased the levels of reactive oxygen species (ROS), which were abrogated by transfecting p22phox or NOX4 antisense vectors. p22phox and NOX4 also contributed to hU-II-induced activation of extracellular signal-regulated kinase 1/2, p38 mitogen-activated protein kinase, c-Jun N-terminal kinase, and protein kinase B (Akt). Furthermore, hU-II increased the expression of PAI-1 and enhanced PASMC proliferation in an NADPH oxidase- and kinase-dependent manner.
CONCLUSIONS: hU-II is a potent activator of ROS generation by NADPH oxidase in PASMCs, leading to redox-sensitive activation of mitogen-activated protein kinases and Akt and subsequently to enhanced PAI-1 expression and increased proliferation. These findings suggest that hU-II may play a novel role in pulmonary hypertension by promoting remodeling processes via activation of NADPH oxidases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15618545     DOI: 10.1161/01.ATV.0000154279.98244.eb

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  57 in total

Review 1.  PPARgamma as a potential therapeutic target in pulmonary hypertension.

Authors:  Roy L Sutliff; Bum-Yong Kang; C Michael Hart
Journal:  Ther Adv Respir Dis       Date:  2010-06       Impact factor: 4.031

2.  Urotensin-II in systemic sclerosis: a new peptide in pathogenesis.

Authors:  Yavuz Pehlivan; Ahmet Mesut Onat; Gazi Comez; Taner Babacan
Journal:  Clin Rheumatol       Date:  2011-01-28       Impact factor: 2.980

Review 3.  Early growth response transcription factors: key mediators of fibrosis and novel targets for anti-fibrotic therapy.

Authors:  Swati Bhattacharyya; Minghua Wu; Feng Fang; Warren Tourtellotte; Carol Feghali-Bostwick; John Varga
Journal:  Matrix Biol       Date:  2011-04-13       Impact factor: 11.583

4.  Protein expression of urotensin II, urotensin-related peptide and their receptor in the lungs of patients with lymphangioleiomyomatosis.

Authors:  Arnold S Kristof; Zhipeng You; Yin-Shan Han; Adel Giaid
Journal:  Peptides       Date:  2010-04-28       Impact factor: 3.750

5.  Urotensin II-induced insulin resistance is mediated by NADPH oxidase-derived reactive oxygen species in HepG2 cells.

Authors:  Ying-Ying Li; Zheng-Ming Shi; Xiao-Yong Yu; Ping Feng; Xue-Jiang Wang
Journal:  World J Gastroenterol       Date:  2016-07-07       Impact factor: 5.742

Review 6.  NADPH oxidase-derived reactive oxygen species in cardiac pathophysiology.

Authors:  Alison Cave; David Grieve; Sofian Johar; Min Zhang; Ajay M Shah
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-12-29       Impact factor: 6.237

Review 7.  Biochemistry, physiology, and pathophysiology of NADPH oxidases in the cardiovascular system.

Authors:  Bernard Lassègue; Alejandra San Martín; Kathy K Griendling
Journal:  Circ Res       Date:  2012-05-11       Impact factor: 17.367

Review 8.  NADPH oxidases as a source of oxidative stress and molecular target in ischemia/reperfusion injury.

Authors:  Pamela W M Kleikers; K Wingler; J J R Hermans; I Diebold; S Altenhöfer; K A Radermacher; B Janssen; A Görlach; H H H W Schmidt
Journal:  J Mol Med (Berl)       Date:  2012-10-23       Impact factor: 4.599

Review 9.  TGF-β signaling in tissue fibrosis: redox controls, target genes and therapeutic opportunities.

Authors:  Rohan Samarakoon; Jessica M Overstreet; Paul J Higgins
Journal:  Cell Signal       Date:  2012-10-11       Impact factor: 4.315

Review 10.  Regulation of NADPH oxidase in vascular endothelium: the role of phospholipases, protein kinases, and cytoskeletal proteins.

Authors:  Srikanth Pendyala; Peter V Usatyuk; Irina A Gorshkova; Joe G N Garcia; Viswanathan Natarajan
Journal:  Antioxid Redox Signal       Date:  2009-04       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.